Tolerance mechanisms of human-residential bifidobacteria against lysozyme

Anaerobe. 2017 Oct:47:104-110. doi: 10.1016/j.anaerobe.2017.05.001. Epub 2017 May 3.

Abstract

We previously reported that lysozyme present in breast milk is a selection factor for bifidobacterial colonization in infant human intestines. This study is aimed at examining their underlying mechanisms. Human-residential bifidobacteria (HRB) generally exhibited higher tolerance than non-HRB to lysozymes, except B. bifidum subspecies. To assess the involvement of enzymatic activity of lysozyme, peptidoglycan (PG) was isolated and the degree of O-acetylation (O-Ac) in 19 strains, including both HRB and non-HRB, was determined. Variety in the degree of O-Ac was observed among each of the Bifidobacterium species; however, all purified PGs were found to be tolerant to lysozyme, independent of their O-Ac degree. In addition, De-O-Ac of PGs affected the sensitivity to lysozyme of only B. longum-derived PG. To examine the non-enzymatic antibacterial activity of lysozyme on bifidobacteria, lysozyme was heat-denatured. The HRB and non-HRB strains exhibited similar patterns of susceptibility to intact lysozyme as they did to heat-denatured lysozyme. In addition, strains of B. bifidum (30 strains), which showed various tolerance of lysozyme, also exhibited similar patterns of susceptibility to intact lysozyme as they did to heat-denatured lysozyme. These results suggest that bifidobacteria are resistant to the peptidoglycan-degrading property of lysozyme, and the tolerance to lysozyme among some HRB strains is due to resistance to the non-enzymatic antibacterial activity of lysozyme.

MeSH terms

  • Acetylation
  • Anti-Infective Agents / metabolism*
  • Bifidobacterium / chemistry
  • Bifidobacterium / drug effects*
  • Bifidobacterium / physiology*
  • Cell Wall / chemistry
  • Humans
  • Hydrolysis
  • Muramidase / metabolism*
  • Peptidoglycan / chemistry
  • Peptidoglycan / isolation & purification
  • Peptidoglycan / metabolism

Substances

  • Anti-Infective Agents
  • Peptidoglycan
  • Muramidase